# A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours

> **NCT03468426** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 252 (actual)

## Conditions studied

- Non-squamous, Non-Small-Cell Lung Cancer
- Neoplasms

## Interventions

- **DRUG:** BI 836880
- **DRUG:** Ezabenlimab

## Key facts

- **NCT ID:** NCT03468426
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-07-05
- **Primary completion:** 2024-07-31
- **Final completion:** 2024-09-12
- **Target enrollment:** 252 (ACTUAL)
- **Last updated:** 2025-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03468426

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03468426, "A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03468426. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*